膦甲酸钠氯化钠注射液在血液病合并EBV感染中的疗效和安全性分析

Efficacy and safety of foscarnet sodium in the treatment of EBV infection in hematopathy patients

目的:探讨膦甲酸钠氯化钠注射液治疗血液病合并EBV感染的疗效和安全性。方法:回顾分析86例应用膦甲酸钠氯化钠注射液治疗的血液病合并EBV感染的患者情况,记录患者治疗前后EBV-DNA拷贝数变化,观察临床症状变化。疗效评价参数:转阴率、显效率、总体有效率、无效率,以及不良事件发生率等。结果:86例患者治疗前后EBV-DNA拷贝数比较差异有统计学意义(P=0.039)。其中EBV-DNA拷贝数转阴52例,转阴率60.47%;显效6例,显效率6.98%;总体有效率67.44%(58/86);无效28例,无效率32.56%。不良反应发生率30.23%(26/86),无严重不良反应。结论:膦甲酸钠可以明显降低血液病患者EBV感染的病毒载量,对发热、肝脾肿大等有明显治疗作用,无严重不良反应,可以安全应用于临床。

Objective：To investigate the clinical effect and safety of foscarnet sodium in treatment of hematopathy patients combined with EBV-infection.Method：We retrospectively analyzed 86 inpatients of hematopathy combined with EBV-infection treated with foscarnet sodium.We recorded the changes of EBV-DNA copy number before and after treatment,and observed the treatment effect.Evaluation parameters included the negative rate,significant efficiency,overall efficiency,inefficiency,and the incidence of adverse events.Result：Among 86 cases,there was significant difference in EBV-DNA copy numbers before and after treatment（P=0.039）.There were 52 patients with EBV-DNA copy number of negative,the negative rate was 60.47%,6 patients had a significant effect and the significant efficiency was 6.98%,the total effective rate was 67.44%（58/86）,invalid number of cases was28 and invalid rate was 32.56%.The incidence of adverse reactions was 30.23%（26/86）,no serious adverse reactions were observed.Conclusion：Foscarnet sodium and sodium chloride injection can significantly reduce viral load in hematopathy patients combined with EBV-infection,it has significant therapeutic effects on fever,liver and spleen enlargement,with no serious adverse reactions.It can be safely used in clinic.